Extended-spectrum β-lactamases in ambulatory care: a clinical perspective  by Rodríguez-Baño, J. & Navarro, M.D.
REVIEW
Extended-spectrum b-lactamases in ambulatory care: a clinical perspective
J. Rodrı´guez-Ban˜o and M. D. Navarro
Seccio´n de Enfermedades Infecciosas, Hospital Universitario Virgen Macarena, Sevilla, Spain
ABSTRACT
Extended-spectrum b-lactamase (ESBL)-producing organisms are emerging as a cause of infection in
outpatients in many areas of the world. Most of these involve urinary tract infections caused by
Escherichia coli harbouring CTX-M types of ESBLs. Risk-factors for such infections include older age and
previous use of quinolones and cephalosporins. Oral alternatives for such infections are limited. These
organisms may also cause some community-acquired life-threatening infections, such as bacteraemic
urinary tract or intra-abdominal infections. Patients with these infections are at increased probability of
receiving inappropriate empirical treatment. More studies addressing the risk-factors and therapeutic
options for these infections are needed.
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Until recently, the microorganisms producing
extended-spectrum b-lactamases (ESBLs) have
mainly caused problems in acute-care hospitals
[1]. However, these organisms have been spread-
ing to other healthcare facilities such as nursing
homes [2], and, during recent years, infections
caused by ESBL-producing organisms have been
increasingly diagnosed in outpatients [3–5]. The
leading role in this new situation is being played
by ESBL-producing Escherichia coli, and, at the
molecular level, by the genes encoding for CTX-M
types of ESBLS [6], which are rapidly spreading
throughout the world [7].
From a clinical perspective, the impact of this
phenomenon is very relevant. ESBL-producing
organisms are not only resistant to penicillins and
cephalosporins, but are also frequently resistant
to trimethoprim–sulphamethoxazole and ﬂuoro-
quinolones [1]. Thus, these organisms may be
resistant to most of the antimicrobial agents that
are usually recommended for the treatment of
community-acquired infections caused by entero-
bacteria. The situation is even more worrisome
because they may also cause severe invasive
infections. This review will summarise the
epidemiology, risk-factors, clinical features and
therapeutic options for infections caused by
ESBL-producing organisms in outpatients.
EPIDEMIOLOGICAL OVERVIEW
OF INFECTIONS CAUSED BY
ESBL-PRODUCING ORGANISMS
IN OUTPATIENTS
ESBL-producing organisms have been emerging
as relevant community pathogens during the last
decade in many areas of the world. The evolution
of ESBL-producing organisms was studied from
1995 to 2002 in an area of 500 000 inhabitants in
Seville, Spain [8]. From 1995 to 1998, only 14
strains of E. coli were ESBL producers. The situ-
ation abruptly changed in 2000, when 53 isolates
of ESBL-producing E. coli were detected, and
there was a further increase during 2001 and
2002 (106 and 114 isolates, respectively). Thus, the
percentage of E. coli isolates that were ESBL
producers increased from 0.3% in 1995 to 4.8%
in 2002. During the same period, there was a
signiﬁcant decrease in the rates of ESBL-produc-
ing Klebsiella pneumoniae isolates, following the
control of nosocomial transmission of this organ-
ism. However, many data showed that ESBL-
producing E. coli strains were not replacing
K. pneumoniae strains, but constituted a new and
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distinct phenomenon; while most ESBL-produc-
ing K. pneumoniae strains were clonally related,
produced ESBLs of the SHV and TEM families
almost exclusively, and were mainly isolated
from hospitalised patients, ESBL-producing
E. coli strains were not clonally related, the pre-
dominant ESBLs produced belonged to the CTX-
M family, and approximately half were isolated
from outpatients [8,9]. These features were con-
ﬁrmed in a speciﬁc clinical and molecular inves-
tigation of the epidemiology of ESBL-producing
E. coli in outpatients [3].
As an example of the explosive dissemination
of the CTX-M enzymes, CTX-M-14 (an enzyme
belonging to the CTX-M-9 group that was char-
acterised in Taiwan [10]) emerged almost at the
same time in such distant areas as Spain [11,12].
Also, intercontinental spread of many other CTX-
M enzymes has rapidly occurred. Such efﬁcacious
dissemination has been related to the fact that the
genes encoding for these enzymes are associated
with highly transmissible genetic mobile elements
[6]. In fact, most isolates of E. coli harbouring
these enzymes have been found to be clonally
unrelated [3,5,11–13]. However, clonal spread has
also been described both in the community and in
healthcare facilities [14], and it seems to be
particularly frequent in the case of strains har-
bouring CTX-M-15 [15,16], which further contrib-
utes to the problem of dissemination.
The prevalence of colonisation with ESBL-
producing enterobacteria in the general popula-
tion is largely unknown. There are probably
substantial geographical variations. Most data
come from studies in which the presence of
ESBL-producing enterobacteria has been investi-
gated in faecal samples from patients with diar-
rhoea. In Barcelona, Spain, Mirelis et al. [17]
studied the presence of ESBL-producing entero-
bacteria in faecal samples obtained from outpa-
tients presenting at their hospital during three
different periods. The percentage of carriers
increased from 2.1% (February–May 2001) to
3.8% (April–June 2002) and to 7.5% (October
2002). In Madrid, Spain, Valverde et al. searched
for the presence of ESBL-producing enterobacte-
ria in faecal samples collected during 1999 and
2003 [18]. The percentage of outpatients from
whom ESBL-producing enterobacteria were iso-
lated signiﬁcantly increased from 0.7% in 1999 to
5.5% in 2003, when all the ESBL-producing
isolates found were E. coli. The most frequent
types of ESBL found were CTX-M, followed by
SHV. In 2003, faecal samples from healthy volun-
teers were also studied and the rate of colonisa-
tion was 3.7%. In York, UK, Munday et al. studied
1000 faecal samples (565 from outpatients) during
October–December 2003 [5]. They found ESBL-
producing E. coli in nine samples, eight of which
were obtained from outpatients (rate in outpa-
tients, 1.4%). All these isolates produced CTX-M
enzymes (ﬁve CTX-M-15, three CTX-M-14 and
one CTX-M-9). The rate for faecal carriage was
7% in a study performed in healthy executives in
India [19] but was much lower in a study in
healthy children in Bolivia and Peru (0.1%) [20].
Data concerning the population-based rates for
infections due to ESBL-producing E. coli are
scarce. In Calgary, Pitout et al. found a rate of
5.5 cases per 100 000 population during 2000–
2002; only 29% of the cases involved nosocomial
infections [14]. Similar rates were found in a
multicentre study performed in Spain including
only community-acquired infections. With regard
to speciﬁc data concerning community-acquired
urinary tract infections (UTIs), the percentage of
ESBL-producing E. coli isolates ranged from 1.4%
to 3.3% in studies from Seville, Barcelona and the
Gaza Strip [3,21,22]. There are even fewer data
concerning invasive infections. In Seville, 6.5% of
community-acquired bacteraemia cases due to
E. coli during 2001–2005 were caused by ESBL-
producing isolates, with an increasing trend [23].
In a multicentre study on the susceptibility
patterns of Enterobacteriaceae isolated from pat-
ients with intra-abdominal infections in Spain, 15
of 398 (3.7%) isolates from community-acquired
infections were ESBL producers [24]. Again, the
rates may be very different in different geograph-
ical areas.
RISK-FACTORS FOR ESBL
COLONISATION AND
INFECTION IN OUTPATIENTS
Several groups have investigated the variables
associated with the isolation of ESBL-producing
E. coli in outpatients. Three case-control studies
have been published, two of them from different
areas in Spain and the other from Israel (Table 1)
[3,21,25]. The methodological differences between
them may account for the different results.
Nevertheless, previous use of antimicrobials that
may select for ESBL-producing isolates, such as
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quinolones (due to the high frequency of
co-resistance) and cephalosporins, were found to
be a risk-factor in all three studies. The fact that
previous hospitalisation was a risk-factor in the
two bigger studies [3,25] should not lead to the
conclusion that the organisms were acquired
during the hospital stay, although this could be
the case for those patients with ESBL-producing
K. pneumoniae isolates that were also included in
the study from Israel. Our data strongly suggest
that at least the CTX-M-producing E. coli isolates
were truly community-acquired, and therefore
previous hospitalisation could be a surrogate
marker for other predisposing factors. In fact,
previous hospitalisation was not a risk-factor
when only CTX-M producers were analysed [3].
In their population-based surveillance study
concerning ESBL-producing E. coli in Calgary,
Pitout et al. [4] found that patients aged ‡65 years,
as compared to younger patients, were at in-
creased risk of infection caused by these organ-
isms. Age was also identiﬁed as a risk-factor in
two of the case-control studies [3,24], although
only in male patients in the study from Seville [3].
The situation is less clear with regard to gender.
While Pitout et al. [4] found that female subjects
were at increased risk in all age groups, female
sex was not found to be a risk-factor in any of the
case-control studies. In fact, male gender was an
independent risk-factor in the study by Colodner
et al. [24].
A different approach was used by Ben-Ami
et al. in Israel [26]. These authors screened 241
patients at hospital admission; 26 (10.7%) were
found to be faecal carriers of ESBL-producing
Enterobacteriaceae. The multivariate analysis of
this cohort selected poor functional status, current
antibiotic use, chronic renal insufﬁciency, liver
disease and use of histamine2 receptor antago-
nists as independent risk-factors for faecal car-
riage. As long as the inﬂux of these organisms
from the community may potentially cause prob-
lems inside hospitals, these data might help to
identify high-risk patients to whom infection
control efforts, such as the performance of sur-
veillance cultures, should be directed. It would be
necessary to perform similar studies in other areas,
as risk-factors may differ according to differences
in antimicrobial prescribing practices, rates of
colonisation in the population, etc. However, it is
probably impossible to avoid the inﬂux of these
microorganisms into hospitals, and consequently,T
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other measures, such as reducing the use of
antimicrobials that select ESBL-producing organ-
isms (mainly extended-spectrum cephalosporins
and quinolones), should be considered.
There is less information concerning the spe-
ciﬁc risk-factors involved in the acquisition of
CTX-M-producing E. coli in outpatients. In our
case-control study, all CTX-M-producing isolates
harboured enzymes from the CTX-M-9 group.
Previous ﬂuoroquinolone use, age and a more
severe chronic underlying condition as measured
by the Charlson index were independent risk-
factors [3].
Ben-Ami et al. also performed a case-control
study to investigate the risk-factors for non-
nosocomial bacteraemia caused by ESBL-produc-
ing enterobacteria, using episodes caused by
non-ESBL-producing enterobacteria as controls
[26]. They included 38 cases (15 caused by E. coli,
17 by Klebsiella spp., and six by Proteus mirabilis).
The multivariate analysis selected male gender
and admittance directly from a long-term care
facility as independent risk-factors. However, the
model was only moderately predictive, probably
reﬂecting the heterogeneity of the cases. Our own
group recently reported the preliminary results of
an ongoing case-control study in which the cases
were patients with community-acquired bactera-
emia caused by ESBL-producing E. coli [27]. The
identiﬁed risk-factors were previous antimicro-
bial use, age and structural disease of the urinary
tract. More studies in this ﬁeld are necessary,
because identiﬁcation of risk-factors for commu-
nity-acquired bacteraemia caused by ESBL-pro-
ducing organisms is particularly relevant from a
clinical perspective, as it may help to identify
those patients for whom empirical therapy should
include coverage against ESBL producers.
CLINICAL FEATURES AND
THERAPEUTIC OPTIONS
Although many published studies describe the
microbiological features of ESBL-producing
organisms in outpatients, the information con-
cerning clinical features and the prognosis of
community-acquired infections caused by these
organisms is surprisingly scarce. Many studies,
aimed primarily at describing molecular aspects
of the strains, include isolates obtained from
outpatients and inpatients, and frequently lack
epidemiological and clinical data, so it is not
possible to know whether the infections were
really community-acquired, or which types of
infection were included. Obviously, collecting
precise clinical and follow-up data from outpa-
tients is not an easy task. Since most of the clinical
microbiology laboratories where ESBL-producing
organisms are identiﬁed are located in hospitals, a
collaborative approach involving the hospital and
primary-care levels on one side, and microbio-
logical and clinical specialists on the other, is
necessary.
Community-acquired pathogens that com-
monly cause diarrhoea may also harbour ESBLs
[1]. ESBL-producing Salmonella isolates have been
found in many parts of the world; also, occasional
cases caused by Shiga toxin-producing E. coli,
Shigella and Vibrio cholerae have been described.
As expected, the majority of ESBL-producing
E. coli strains isolated from outpatients come from
urinary samples, with samples from other sour-
ces, e.g., blood, wounds, and respiratory tract,
accounting for <40% of the samples [3,4,9,11,16].
Only one study provides speciﬁc clinical infor-
mation concerning the patients; in that study,
which included 49 cases, the organisms were
isolated from urine samples in 47 patients and
from blood in six (in two patients, both urine and
blood cultures yielded ESBL-producing E. coli)
[3]. Thirty-seven patients (76%) were considered
to have a symptomatic UTI, 11 (22%) had asymp-
tomatic bacteriuria, and one (2%) had acute
cholangitis. Five of the patients with UTIs
(13.5%) were bacteraemic. The patient with cho-
langitis was also bacteraemic. Among the 28
patients who received empirical antimicrobial
therapy, only ten received agents to which the
organism was susceptible in vitro. A UTI relapse
occurred in 13% of patients. None of the patients
in the series died as a consequence of the
infection. Obviously, more studies are needed in
order to gain better knowledge of ESBL-produc-
ing E. coli as a cause of community-acquired
UTIs. In particular, more information about the
importance of these isolates as a cause of compli-
cated UTIs is awaited. Regarding therapy, there
are no published studies analysing the efﬁcacy of
different regimens for UTIs caused by these
strains. Where available, oral fosfomycin is a
reasonable alternative for uncomplicated UTIs
[28], as most isolates are susceptible in vitro [29],
and nitrofurantoin may also be useful [29].
Amoxycillin–clavulanate [30], quinolones and
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trimethoprim–sulphamethoxazole are useful
when the organism is susceptible.
From a clinical perspective, the situation is
more worrisome when patients present with
clinical sepsis. Among all patients from whom
an ESBL-producing E. coli strain is isolated from a
clinical sample, c. 10% are bacteraemic [3,4,9].
In the area of Seville, 6.5% of all community-
acquired episodes of bacteraemia caused by
E. coli have involved ESBL producers during
recent years, but the percentage seems to be
increasing [23]. In the BSAC bacteraemia study
performed in the UK during 2002, 8 ⁄ 210 blood
isolates of E. coli (3.8%) were ESBL producers
[31]. In Israel, Ben-Ami et al. found that 4 ⁄ 50 (8%)
of non-nosocomial bacteraemias due to E. coli
involved ESBL producers during 2003; three of
these cases did not involve previous healthcare
contact [26].
Most of the clinical information about bactera-
emia caused by ESBL-producing organisms is
from studies including only, or predominantly,
nosocomial episodes caused by Klebsiella species.
Two studies that speciﬁcally address episodes
caused by ESBL-producing E. coli also include a
majority of nosocomial episodes [32,33]. There are
some descriptions of anecdotal cases of commu-
nity-acquired bloodstream infections caused by
ESBL-producing enterobacteria [34,35]. We have
recently analysed the epidemiology, prognosis
and clinical features of nosocomial and commu-
nity-acquired bacteraemia caused by ESBL-pro-
ducing E. coli in the area of Seville during 2001–
2005 [23]. Forty-three cases were included; 22
(51%) were non-nosocomially acquired, and eight
(19%) were strictly community-acquired (the
patients had no signiﬁcant healthcare experience
during the previous year). Considering only the
non-nosocomial cases, 45% and 18% of the
patients had obstructive diseases of the urinary
and biliary tract, respectively, so it was not
surprising that the sources of the episodes were
the urinary tract in 55% of the patients and an
intra-abdominal infection in 36% (3 ⁄ 8 of the latter
were biliary tract infections); the source was
unknown in 9%. Half of the patients had recently
received antimicrobials, ﬂuoroquinolones being
the most frequent. Regarding clinical severity,
18% of the patients presented with severe sepsis
or septic shock. Empirical antimicrobial therapy
was appropriate according to in-vitro susceptibil-
ity testing in 64% of the cases, and the crude
mortality rate was 18%. These data emphasise the
clinical relevance of ESBL-producing E. coli as a
potential cause of severe community-acquired
infections. The analysis of the inﬂuence of the
empirical antimicrobial treatment in the progno-
sis included both community and nosocomial
cases; the adjusted mortality was higher in
patients who received cephalosporins or quinol-
ones than in those treated with b-lactam–b-lac-
tamase inhibitors or carbapenems. In the series by
Ho et al., seven patients with apparent ceftazi-
dime-susceptible isolates were treated with this
agent and four of them failed to recover [32]. All
of these data suggest that, similar to what hap-
pens with other ESBL-producing enterobacteria
[1], cephalosporins should not be used for the
empirical treatment of severe infections poten-
tially caused by these organisms. Appropriate
antimicrobial therapy was not associated with
improved survival in another study, but 85% of
the cases received appropriate regimens in that
series [33]. The results of a multicentre study on
bloodstream infections caused by ESBL-produc-
ing E. coli conducted by the Spanish Network for
Research in Infectious Diseases (REIPI) are cur-
rently being analysed; available data indicate that
inappropriate empirical therapy (including ceph-
alosporins) is associated with increased rates of
mortality. However, until more data are available,
it seems prudent for protocols for the empirical
treatment of sepsis potentially caused by E. coli to
be revised in areas where these organisms are
emerging, unless for patients with severe infec-
tions and risk-factors for ESBL-producing isolates.
Carbapenems are considered to be the drugs of
choice for the treatment of severe infections
caused by ESBL-producing organisms [1], and
among them, ertapenem has been suggested as a
reasonable possibility for treatment of these com-
munity-acquired infections, as long as its in-vitro
activity against these isolates is comparable to that
of imipenem and meropenem [36], and it should
exert the least selection pressure for resistance in
Pseudomonas aeruginosa, as compared with other
carbapenems. However, the emergence and
spread of carbapenem resistance is a concern,
and alternatives should be studied. The rate of
aminoglycoside resistance (amikacin, particularly)
among CTX-M-producing E. coli isolates is usu-
ally low; thus, the addition of an aminoglycoside
to the empirical regimen for treatment of commu-
nity-acquired sepsis originating in the urinary
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tract might be a reasonable option for selected
patients at low risk for renal insufﬁciency, until
the susceptibility data of the causative agent are
available (usually 48–72 h). In many areas, the
rates of in-vitro resistance to b-lactam–b-lactamase
inhibitor combinations in ESBL-producing isolates
are high enough to preclude their empirical use
when it is necessary to cover these organisms
[1,3,26]. Some data indicate that temocillin, a semi-
synthetic derivative of ticarcillin that is available
in some countries, has good in-vitro activity
against ESBL-producing E. coli [37], but no clinical
experience with this antimicrobial has been pub-
lished. Also, tigecycline, a new compound that has
been approved for complicated intra-abdominal
and soft-tissue infections, has shown excellent
in-vitro activity against ESBL-producing isolates
and is another alternative for treatment of such
infections [38].
CONCLUSION
ESBL-producing enterobacteria, and particularly
E. coli, have emerged as signiﬁcant pathogens in
outpatients almost worldwide, mainly due to the
spread of CTX-M enzymes. ESBL-producing
E. coli strains mainly cause UTIs in predisposed
patients, but severe infections may also occur.
Since there are not many alternatives for the
treatment of these infections, more studies
addressing the risk-factors, clinical signiﬁcance
and therapeutic options for community-acquired
infections caused by these organisms are needed.
Local surveillance of ESBL-producing enterobac-
teria, and particularly of those causing commu-
nity-acquired bacteraemia, is critical in order to
adequately design recommendations for the
empirical therapy of severe urinary tract and
intra-abdominal infections.
CONFLICT OF INTEREST
STATEMENT
J. Rodrı´guez-Ban˜o has been a consultant for
Wyeth and Merck, and has served as a speaker
for Wyeth, Merck and GlaxoSmithKline.
REFERENCES
1. Paterson DL, Bonomo RA. Extended-spectrum b-lacta-
mases: a clinical update. Clin Microbiol Rev 2005; 18: 657–
686.
2. Wiener J, Quinn JP, Bradford PA et al. Multiple antibiotic-
resistant Klebsiella and Escherichia coli in nursing homes.
JAMA 1999; 281: 517–523.
3. Rodrı´guez-Ban˜o J, Navarro MD, Romero L et al. Epide-
miology and clinical features of infections caused by ex-
tended-spectrum b-lactamase-producing Escherichia coli in
non-hospitalized patients. J Clin Microbiol 2004; 42: 1089–
1094.
4. Pitout JDD, Hanson ND, Church DL, Laupland KB.
Population-based laboratory surveillance for Escherichia
coli-producing extended-spectrum b-lactamases: the
importance of community isolates with blaCTX-M genes.
Clin Infect Dis 2004; 38: 1736–1741.
5. Munday CJ, Whitehead GM, Todd NJ, Campbell M,
Hawkey PM. Predominance and genetic diversity of
community- and hospital-acquired CTX-M extended-
spectrum b-lactamases in York, UK. J Antimicrob Chemother
2004; 54: 628–633.
6. Rodrı´guez-Ban˜o J, Paterson DL. A change in the
epidemiology of infections due to extended-spectrum
b-lactamase-producing organisms. Clin Infect Dis 2006; 42:
935–937.
7. Pitout JDD, Nordmann P, Laupland KB, Poirel L. Emer-
gence of Enterobacteriaceae producing extended-spectrum
b-lactamases (ESBLs) in the community. J Antimicrob Che-
mother 2005; 56: 52–59.
8. Romero L, Lo´pez L, Rodrı´guez-Ban˜o J, Ramo´n Herna´ndez
J, Martı´nez-Martı´nez L, Pascual A. Long-term study of the
frequency of Escherichia coli and Klebsiella pneumoniae iso-
lates producing extended-spectrum b-lactamases. Clin
Microbiol Infect 2005; 11: 625–631.
9. Herna´ndez JR, Pascual A, Canto´n R, Martı´nez-Martı´nez L,
y Grupo de Estudio de Infeccio´n Hospitalaria (GEIH).
Escherichia coli y Klebsiella pneumoniae productores de bet-
alactamasas de espectro extendido en hospitales espan˜oles
(proyecto GEIH-BLEE 2000). Enferm Infecc Microbiol Clin
2003; 21: 77–82.
10. Ma L, Ishii Y, Chang FY, Yamaguchi K, Ho M, Siu LK.
CTX-M-14, a plasmid-mediated CTX-M type extended-
spectrum b-lactamase isolated from Escherichia coli. Anti-
microb Agents Chemother 2002; 46: 1985–1988.
11. Bou G, Cartelle M, Tomas M et al. Identiﬁcation and broad
dissemination of the CTX-M-14 b-lactamase in different
Escherichia coli strains in the northwest area of Spain. J Clin
Microbiol 2002; 40: 4030–4036.
12. Herna´ndez JR, Martı´nez-Martı´nez L, Canto´n R, Coque MT,
Pascual A, The Spanish Group for Nosocomial Infections
(GEIH). Nationwide study of Escherichia coli and Klebsiella
pneumoniae producing extended-spectrum b-lactamases in
Spain. Antimicrob Agents Chemother 2005; 49: 2122–2125.
13. Rodrı´guez-Ban˜o J, Navarro MD, Romero L et al. Clinical
and molecular epidemiology of extended-spectrum b-lac-
tamase-producing Escherichia coli as a cause of nosocomial
infection or colonization: implications for control. Clin
Infect Dis 2006; 42: 37–45.
14. Pitout JDD, Gregson DB, Church DL, Elsayed S, Laupland
KB. Community-wide outbreaks of clonally related CTX-
M-14 b-lactamase-producing Escherichia coli in the Calgary
Health Region. J Clin Microbiol 2005; 43: 2844–2849.
15. Leﬂon-Guibot V, Jurand C, Bonacorsi S et al. Emergence
and spread of three clonally related virulent isolates of
CTX-M-15-producing Escherichia coli with variable resis-
tance to aminoglycosides and tetracycline in a French
Rodrı´guez-Ban˜o and Navarro Extended-spectrum b-lactamases in ambulatory care 109
 2008 The Authors
Journal Compilation  2008 European Society of Clinical Microbiology and Infectious Diseases, CMI, 14 (Suppl. 1), 104–110
geriatric hospital. Antimicrob Agents Chemother 2004; 48:
3736–3742.
16. Oteo J, Navarro C, Cercenado E et al. Spread of Escherichia
coli strains with high-level cefotaxime and ceftazidime
resistance between the community, long-term care facili-
ties, and hospital institutions. J Clin Microbiol 2006; 44:
2359–2366.
17. Mirelis B, Navarro F, Miro´ E, Mesa RJ, Coll P, Prats G.
Community transmission of extended-spectrum b-lac-
tamase. Emerg Infect Dis 2003; 9: 1024–1025.
18. Valverde A, Coque MT, Sa´nchez-Moreno MP, Rolla´n A,
Baquero F, Canto´n R. Dramatic increase in prevalence of
fecal carriage of extended-spectrum b-lactamase-produc-
ing Enterobacteriaceae during nonoutbreak situation in
Spain. J Clin Microbiol 2004; 42: 4769–4775.
19. Rodrigues C, Shukla U, Jog S, Mehta A. Extended-spec-
trum b-lactamase-producing ﬂora in healthy persons.
Emerg Infect Dis 2005; 6: 981–982.
20. Pallecchi L, Malossi M, Mantella A et al. Detection of CTX-
M-type b-lactamase genes in fecal Escherichia coli isolates
from healthy children in Bolivia and Peru. Antimicrob
Agents Chemother 2004; 48: 4556–4561.
21. Calbo E, Romanı´ V, Xercavins M et al. Risk factors for
community-onset urinary tract infections due to Escheri-
chia coli harbouring extended-spectrum b-lactamases.
J Antimicrob Chemother 2006; 57: 780–783.
22. Astal Z, Sharif FA, Abdallah SA, Fahd MI. Extended-
spectrum beta-lactamases in Escherichia coli isolated from
community-acquired urinary tract infections in the Gaza
Strip, Palestine. Ann Saudi Med 2004; 24: 55–57.
23. Rodrı´guez-Ban˜o J, Navarro MD, Romero L et al. Bactere-
mia due to extended-spectrum beta-lactamase-producing
Escherichia coli in the CTX-M era: a new clinical challenge.
Clin Infect Dis 2006; 43: 1407–1414.
24. Baquero F, Cercenado E, Cisterna R et al. Patrones de
sensibilidad a antimicrobianos de Enterobacteriaceae
causantes de infecciones intraabdominales en Espan˜a: re-
sultados del estudio SMART 2003. Rev Esp Quimioter 2006;
19: 51–59.
25. Colodner R, Rock W, Chazan B, Keller N, Guy N, Raz R.
Risk factors for the development of extended-spectrum
b-lactamase-producing bacteria in non-hospitalized pa-
tients. Eur J Clin Microbiol Infect Dis 2004; 23: 163–167.
26. Ben-Ami R, Schwaber MJ, Navon-Venezia S et al. Inﬂux of
extended-spectrum b-lactamase-producing Enterobacteri-
aceae into the hospital. Clin Infect Dis 2006; 42: 925–934.
27. Rodrı´guez-Ban˜o J, Navarro MD, Romero L et al. Commu-
nity-acquired bacteraemia due to extended-spectrum beta-
lactamase-producing Escherichia coli: an emerging clinical
challenge. Clin Microbiol Infect 2005; 11 (suppl 2): 72–73.
28. Pullukcu H, Tasbakan M, Sipahi OR, Yamazhan T, Ayd-
emir S, Ulusoy S. Fosfomycin in the treatment of extended
spectrum beta-lactamase-producing Escherichia coli-related
lower urinary tract infections. Int J Antimicrob Agents 2007;
29: 62–65.
29. de Cueto M, Lo´pez L, Herna´ndez JR, Morillo C, Pascual A.
In vitro activity of fosfomycin against extended-spectrum
betalactamase-producing Escherichia coli and Klebsiella
pneumoniae: a comparison of susceptibility testing proce-
dures. Antimicrob Agents Chemother 2006; 50: 368–370.
30. Lagace´-Wiens PR, Nichol KA, Nicolle LE et al. Treatment
of lower urinary tract infection caused by multidrug-
resistant extended-spectrum-beta-lactamase-producing
Escherichia coli with amoxicillin ⁄ clavulanate: case report
and characterization of the isolate. J Antimicrob Chemother
2006; 57: 1262–1263.
31. Livermore DM, Hawkey PM. CTX-M: changing the face of
ESBLs in the UK. J Antimicrob Chemother 2005; 56: 451–454.
32. Ho PL, Chan WM, Tsang KWT, Wong SSY, Yuong K.
Bacteremia caused by Escherichia coli producing extended-
spectrum beta-lactamase: a case–control study of risk fac-
tors and outcomes. Scand J Infect Dis 2002; 34: 567–573.
33. Metan G, Zarakolu P, Cakir B, Hascelik C, Uzun O. Clin-
ical outcomes and therapeutic options of bloodstream
infections caused by extended-spectrum beta-lactamase-
producing Escherichia coli. Int J Antimicrob Agents 2005; 26:
254–257.
34. Tan BH, Tan AL. Community-acquired bacteremia with an
ESBL-producing Escherichia coli strain—a case report. Int J
Infect Dis 2002; 6: 318–319.
35. Borer A, Gilad J, Menashe G, Peled N, Riesenberg K,
Schlaellfer F. Extended-spectrum beta-lactamase-produc-
ing Enterobacteriaceae strains in community-acquired
bacteremia in Southern Israel. Med Sci Monit 2002; 8:
CR44–CR47.
36. Herna´ndez JR, Velasco C, Romero L, Martı´nez-Martı´nez L,
Pascual A. Comparative in vitro activity of ertapenem
against extended-spectrum beta-lactamase-producing
Escherichia coli and Klebsiella pneumoniae isolated in Spain.
Int J Antimicrob Agents 2006; 28: 457–459.
37. Rodriguez-Villalobos H, Malaviolle V, Frankard J, de
Mendonca R, Nonhoff C, Struelens MJ. In vitro activity of
temocillin against extended spectrum beta-lactamase-pro-
ducing Escherichia coli. J Antimicrob Chemother 2006; 57:
771–774.
38. Morosini MI, Garcia-Castillo M, Coque TM et al. Antibiotic
coresistance in extended-spectrum-beta-lactamase-pro-
ducing Enterobacteriaceae and in vitro activity of
tigecycline. Antimicrob Agents Chemother 2006; 50: 2695–
2699.
110 Clinical Microbiology and Infection, Volume 14, Supplement 1, January 2008
 2008 The Authors
Journal Compilation  2008 European Society of Clinical Microbiology and Infectious Diseases, CMI, 14 (Suppl. 1), 104–110
